ArticleFrontiers in oncology2026
The role of tumor budding in the prognosis of patient with locally advanced colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on the use of tumor budding (BD), an important survival marker for colorectal carcinoma (CRC), is still ongoing. In the present study, we aimed to determine the effectiveness of BD on prognosis in locally advanced CRC cases. In our study, CRC cases operated on between 2005 and 2015 were examined.BD was calculated using a standard methodology. A significant relationship was found between poor prognostic factors and BD (lymphatic invasion [p=0.008], tumor perforation [p=0.023], locally advanced-stage [p=0.023], positive surgical margins [p=0.005], advanced pT [p<0.001], and high grade [p<0.001]). Additionally, we found poor prognostic factors to be an independent risk factor in the regression analysis for BD (OS = 2.85 [1.15-3.48], p=0.001). Furthermore, correlation (r=0.695) and repeatability analysis (Kappa=0.56-0.75) for BD data indicated that it was successful (ROC: 10.23; AUC = 0.822 [0.714-0.943]). There was a significant difference in survival on univariate analysis for BD (RFS<0.001, OS = 0.001). In multivariate analysis, BD was shown to be an independent poor prognostic factor for CRC (RFS: HR = 2.96 [1.48-3.57], p<0001), and OS: HR = 2.69 [1.38-3.70], p<0.001). Our study indicates that BD detected using a standard methodology is a suitable predictive factor in determining poor prognosis in locally advanced CRC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.